Blue digital media to highlight $IBO narrativeThe UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
$IBO an investor’s alluring stock investment$IBO has been elastic through the ebbs and flows of the market and have always maintained a tight toe hold in the Canadian venture exchange, its consistency to this day is what intrigues investors globally, the shares are trading at $0.05 with no such recorded loss
$HEM recoups legal guardianship of its lost intellectual The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01 clinical trial data in North America and South Africa.
Efficacy of NCP-01 a futuristic product by Hemostemix
Neuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
$IBO soon to commission ultra- modern addiction treatment centreAt the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
UI CEO’s thrilled to work with Blue Digital Media"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." Alike Blue Digital Media’s expertise radar
Nick Karos excited by listing of UI on Frankfurt stock exchange Universal Ibogaine Inc. CEO made a statement "Our capital markets and investor relations strategy includes the FSE listing. We recently began trading on the OTCQB Exchange in the United States, and curiosity in the UI story is growing in Europe, particularly Germany. With a mushrooming market and interest in psychedelic medications, Germany has a reputation for innovation and leadership."
$IBO contract with blue digital media dictates further benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
Hemostemix Inc. interest payment on convertible debentureHemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
$PQE moving ahead fiercely with an unstoppable forceThe stock today observed a brief rise in the value per share since its previous close, and the shares are actively being traded on TSX-V at $.245 per unit
P
$PQE moving ahead fiercely with an unstoppable forceThe stock today observed a brief rise in the value per share since its previous close, and the shares are actively being traded on TSX-V at $.24 per unit
P






















